Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2017

Open Access 01-04-2017 | Review Article

Targets and probes for non-invasive imaging of β-cells

Authors: Andreas Jodal, Roger Schibli, Martin Béhé

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2017

Login to get access

Abstract

β-cells, located in the islets of the pancreas, are responsible for production and secretion of insulin and play a crucial role in blood sugar regulation. Pathologic β-cells often cause serious medical conditions affecting blood glucose level, which severely impact life quality and are life-threatening if untreated. With 347 million patients, diabetes is one of the most prevalent diseases, and will continue to be one of the largest socioeconomic challenges in the future. The diagnosis still relies mainly on indirect methods like blood sugar measurements. A non-invasive diagnostic imaging modality would allow direct evaluation of β-cell mass and would be a huge step towards personalized medicine. Hyperinsulinism is another serious condition caused by β-cells that excessively secrete insulin, like for instance β-cell hyperplasia and insulinomas. Treatment options with drugs are normally not curative, whereas curative procedures usually consist of the resection of affected regions for which, however, an exact localization of the foci is necessary. In this review, we describe potential tracers under development for targeting β-cells with focus on radiotracers for PET and SPECT imaging, which allow the non-invasive visualization of β-cells. We discuss either the advantages or limitations for the various tracers and modalities. This article concludes with an outlook on future developments and discuss the potential of new imaging probes including dual probes that utilize functionalities for both a radioactive and optical moiety as well as for theranostic applications.
Literature
1.
Atkinson MA. The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2(11).
2.
Elayat AA, el-Naggar MM, Tahir M. An immunocytochemical and morphometric study of the rat pancreatic islets. J Anat. 1995;186(Pt 3):629–37.PubMedPubMedCentral
3.
Wang X, Misawa R, Zielinski MC, Cowen P, Jo J, Periwal V, et al. Regional differences in islet distribution in the human pancreas—preferential beta-cell loss in the head region in patients with type 2 diabetes. Kay TWH, editor. PLoS ONE. 2013;8(6):e67454.
4.
Ratner RE. Glycemic control in the prevention of diabetic complications. Clin Cornerstone. 2001;4(2):24–37.PubMedCrossRef
5.
6.
Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2 · 7 million participants. Lancet. 2011;378(9785):31–40.PubMedCrossRef
7.
van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011;91(1):79–118.PubMedCrossRef
8.
Caro JF, Dohm LG, Pories WJ, Sinha MK. Cellular alterations in liver, skeletal muscle, and adipose tissue responsible for insulin resistance in obesity and type II diabetes. Diabetes Metab Rev. 1989;5(8):665–89.PubMedCrossRef
9.
10.
Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS. Increased β-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes Am Diabetes Assoc. 1999;48(5):989–96.
11.
12.
Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med. 2010;363(13):1289–90.PubMedCrossRef
13.
Dixon S, Tapping CR, Walker JN, Bratby M, Anthony S, Boardman P, et al. The role of interventional radiology and imaging in pancreatic islet cell transplantation. Clin Radiol. 2012;67(9):923–31.PubMedCrossRef
14.
Kriz J, Jirak D, Berkova Z, Herynek V, Lodererova A, Girman P, et al. Detection of pancreatic islet allograft impairment in advance of functional failure using magnetic resonance imaging. Transplant Int. 2011;25(2):250–60.CrossRef
15.
Arya V, Mohammed Z, Blankenstein O, De Lonlay P, Hussain K. Hyperinsulinaemic hypoglycaemia. Horm Metab Res. 2014;46(03):157–70.PubMedCrossRef
16.
Raffel A, Krausch MM, Anlauf M, Wieben D, Braunstein S, Klöppel G, et al. Diffuse nesidioblastosis as a cause of hyperinsulinemic hypoglycemia in adults: a diagnostic and therapeutic challenge. Surgery. 2007;141(2):179–84.PubMedCrossRef
17.
18.
Boukhman MP, Karam JM, Shaver J, Siperstein AE, DeLorimier AA, Clark OH. Localization of insulinomas. Arch Surg. 1999;134(8):818–22.PubMedCrossRef
19.
Fagerholm V, Mikkola KK, Ishizu T, Arponen E, Kauhanen S, Nagren K, et al. Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med. 2010;51(9):1439–46.PubMedCrossRef
20.
Jahan M, Eriksson O, Johnström P, Korsgren O, Sundin A, Johansson L, et al. Decreased defluorination using the novel beta-cell imaging agent [18F]FE-DTBZ-d4 in pigs examined by PET. EJNMMI Research. Springer Open Ltd; 2011;1(1):33.
21.
Eriksson O, Jahan M, Johnström P, Korsgren O, Sundin A, Halldin C, et al. In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol. 2010;37(3):357–63.PubMedCrossRef
22.
Normandin MD, Petersen KF, Ding YS, Lin SF, Naik S, Fowles K, et al. In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-Fluoropropyl-Dihydrotetrabenazine and PET. J Nucl Med. 2012;53(6):908–16.PubMedPubMedCentralCrossRef
23.
Harris PE, Farwell MD, Ichise M. PET quantification of pancreatic VMAT 2 binding using (+) and (−) enantiomers of [18F]FP-DTBZ in baboons. Nucl Med Biol. 2013;40(1):60–4.PubMedCrossRef
24.
Schneider S, Feilen PJ, Schreckenberger M, Schwanstecher M, Schwanstecher C, Buchholz HG, et al. In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans. Exp Clin Endocrinol Diabetes. 2005;113(7):388–95.PubMedCrossRef
25.
Oh C-S, Kohanim S, Kong F-L, Song H-C, Huynh N, Mendez R, et al. Sulfonylurea receptor as a target for molecular imaging of pancreas beta cells with 99mTc-DTPA-glipizide. Ann Nucl Med. 2012;26(3):253–61.PubMedCrossRef
26.
27.
28.
Ueberberg S, Meier JJ, Waengler C, Schechinger W, Dietrich JW, Tannapfel A, et al. Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic β- or α-cells in vivo. Diabetes. 2009;58(10):2324–34.PubMedPubMedCentralCrossRef
29.
Balla DZ, Gottschalk S, Shajan G, Ueberberg S, Schneider S, Hardtke-Wolenski M, et al. In vivo visualization of single native pancreatic islets in the mouse. Aime S, Muller RN, editors. Contrast Media Mol. Imaging. 2013;8(6):495–504.
30.
Vats D, Wang H, Esterhazy D, Dikaiou K, Danzer C, Honer M, et al. Multimodal imaging of pancreatic beta cells in vivo by targeting transmembrane protein 27 (TMEM27). Diabetologia. 2012;55(9):2407–16.PubMedPubMedCentralCrossRef
31.
Eriksson O, Eich T, Sundin A, Tibell A, Tufveson G, Andersson H, et al. Positron emission tomography in clinical islet transplantation. Am J Transplant. 2009;9(12):2816–24.PubMedCrossRef
32.
Malaisse WJ, Damhaut P, Malaisse-Lagae F, Ladriere L, Olivares E, Goldman S. Fate of 2-deoxy-2-[18F]fluoro-d-glucose in control and diabetic rats. Int J Mol Med. 2000;5(5):525–32.PubMed
33.
Imperiale A, Sebag F, Vix M, Castinetti F, Kessler L, Moreau F, et al. 18F-FDOPA PET/CT imaging of insulinoma revisited. Eur J Nucl Med Mol Imaging. 2015;42(3):409–18.PubMedCrossRef
34.
Gopal-Kothandapani JS, Hussain K. Congenital hyperinsulinism: role of fluorine-18L-3, 4 hydroxyphenylalanine positron emission tomography scanning. World J Radiol. 2014;6(6):252–60.PubMedPubMedCentralCrossRef
35.
Kauhanen S, Seppänen M, Minn H, Nuutila P. Clinical PET imaging of insulinoma and beta-cell hyperplasia. Curr Pharm Des. 2010;16(14):1550–60.PubMedCrossRef
36.
Eriksson O, Espes D, Selvaraju RK, Jansson E, Antoni G, Sorensen J, et al. Positron emission tomography Ligand [11C]5-Hydroxy-tryptophan can be used as a surrogate marker for the human endocrine pancreas. Diabetes. 2014;63(10):3428–37.PubMedCrossRef
37.
Di Gialleonardo V, de Vries EFJ, Di Girolamo M, Quintero AM, Dierckx RAJO, Signore A. Imaging of β-cell mass and insulitis in insulin-dependent (type 1) diabetes mellitus. Endocr Rev. 2012;33(6):892–919.PubMedCrossRef
38.
Rubí B, Ljubicic S, Pournourmohammadi S, Carobbio S, Armanet M, Bartley C, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem. 2005;280(44):36824–32.PubMedCrossRef
39.
Garcia A, Mirbolooki MR, Constantinescu C, Pan ML, Sevrioukov E, Milne N, et al. 18F-Fallypride PET of pancreatic islets: in vitro and in vivo rodent studies. J Nucl Med. 2011;52(7):1125–32.PubMedCrossRef
40.
Garcia A, Venugopal A, Pan M-L, Mukherjee J. Imaging pancreas in healthy and diabetic rodent model using [18F]fallypride positron emission tomography/computed tomography. Diabetes Technol Ther. 2014;16(10):640–3.PubMedPubMedCentralCrossRef
41.
Lv J, Pan Y, Li X, Cheng D, Liu S, Shi H, et al. The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide. Holscher C, editor. PLoS ONE. 2014;9(5):e96833.
42.
Lubag AJ, De Leon-Rodriguez LM, Burgess SC, Sherry AD. Noninvasive MRI of β-cell function using a Zn2+-responsive contrast agent. Proc Natl Acad Sci U S A. 2011;108(45):18400–5.PubMedPubMedCentralCrossRef
43.
Wild D, Wicki A, Mansi R, Behe M, Keil B, Bernhardt P, et al. Exendin-4-based radiopharmaceuticals for glucagon-like peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med. 2010;51(7):1059–67.PubMedCrossRef
44.
Lamprianou S, Immonen R, Nabuurs C, Gjinovci A, Vinet L, Montet XCR, et al. High-resolution magnetic resonance imaging quantitatively detects individual pancreatic islets. Diabetes. 2011;60(11):2853–60.PubMedPubMedCentralCrossRef
45.
Antkowiak PF, Vandsburger MH, Epstein FH. Quantitative pancreatic β cell MRI using manganese-enhanced look-locker imaging and two-site water exchange analysis. Magn Reson Med. 2011;67(6):1730–9.PubMedCrossRef
46.
Dhyani AH, Fan X, Leoni L, Haque M, Roman BB. Empirical mathematical model for dynamic manganese-enhanced MRI of the murine pancreas for assessment of β-cell function. Magn Reson Imaging. Elsevier Inc; 2013;31(4):508–14.
47.
Botsikas D, Terraz S, Vinet L, Lamprianou S, Becker CD, Bosco D, et al. Pancreatic magnetic resonance imaging after manganese injection distinguishes type 2 diabetic and normoglycemic patients. Islets. 2012;4(3):243–8.PubMedPubMedCentralCrossRef
48.
Kang N-Y, Lee S-C, Park S-J, Ha H-H, Yun S-W, Kostromina E, et al. Visualization and isolation of Langerhans islets by a fluorescent probe PiY. Angew Chem Int Ed. 2013;52(33):8557–60.CrossRef
49.
Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Béhé M, et al. [Lys40 (Ahx-DTPA-111In) NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor–targeted therapy for insulinoma. Clin Cancer Res. 2007;13(12):3696–705.
50.
Wild D, Béhé M, Wicki A, Storch D, Waser B, Gotthardt M, et al. [Lys40(Ahx-DTPA-111In)NH2]-exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47(12):2025–33.PubMed
51.
Christ E, Wild D, Ederer S, Behe M, Nicolas G. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol. 2013;1(2):115–22.PubMedCrossRef
52.
Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94(11):4398–405.PubMedCrossRef
53.
Sowa-Staszczak A, Pach D, Mikołajczak R, Mäcke H, Jabrocka-Hybel A, Stefańska A, et al. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging. 2013;40(4):524–31.PubMedCrossRef
54.
Selvaraju RK, Velikyan I, Johansson L, Wu Z, Todorov I, Shively J, et al. In vivo imaging of the glucagon-like peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4. J Nucl Med. 2013;54(8):1458–63.PubMedCrossRef
55.
Wu Z, Todorov I, Li L, Bading JR, Li Z, Nair I, et al. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-exendin-4 by targeting GLP-1 receptor. Bioconjugate Chem. 2011;22(8):1587–94.CrossRef
56.
Mikkola K, Kirsi M, Yim C-B, Cheng-Bin Y, Fagerholm V, Veronica F, et al. 64Cu- and 68Ga-labelled [Nle14, Lys40(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol. 2014;16(2):255–63.PubMedCrossRef
57.
Kiesewetter DO, Gao H, Ma Y, Niu G, Quan Q, Guo N, et al. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging. 2012;39(3):463–73.PubMedCrossRef
58.
Wu Z, Liu S, Hassink M, Nair I, Park R, Li L, et al. Development and evaluation of 18F-TTCO-Cys40-exendin-4: a PET probe for imaging transplanted islets. J Nucl Med. 2013;54(2):244–51.PubMedCrossRef
59.
Keliher EJ, Reiner T, Thurber GM, Upadhyay R, Weissleder R. Efficient 18F-labeling of synthetic exendin-4 analogues for imaging beta cells. Chem Open. 2012;1(4):177–83.
60.
Yim C-B, Mikkola K, Fagerholm V, Elomaa V-V, Ishizu T, Rajander J, et al. Synthesis and preclinical characterization of [64Cu]NODAGA-MAL-exendin-4 with a N ε-maleoyl-l-lysyl-glycine linkage. Nucl Med Biol. 2013;40(8):1006–12.PubMedCrossRef
61.
Kiesewetter DO, Guo N, Guo J, Gao H, Zhu L, Ma Y, et al. Evaluation of an [18F]AlF-NOTA analog of exendin-4 for imaging of GLP-1 receptor in insulinoma. Theranostics. 2012;2(10):999–1009.PubMedPubMedCentralCrossRef
62.
Waser B, Reubi JC. Value of the radiolabelled GLP-1 receptor antagonist exendin(9–39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans. Eur J Nucl Med Mol Imaging. 2011;38(6):1054–8.PubMedCrossRef
63.
Waser B, Reubi JC. Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues. Eur J Nucl Med Mol Imaging. 2014;41(6):1166–71.PubMedCrossRef
64.
Gotthardt M, Lalyko G, van Eerd-Vismale J, Keil B, Schurrat T, Hower M, et al. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept. 2006;137(3):162–7.PubMedCrossRef
65.
Brom M, Oyen WJG, Joosten L, Gotthardt M, Boerman OC. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging. 2010;37(7):1345–55.PubMedPubMedCentralCrossRef
66.
Brom M, Joosten L, Oyen WJG, Gotthardt M, Boerman OC. Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas. Contrast Media Mol Imaging. 2012;7(2):160–6.PubMedPubMedCentralCrossRef
67.
Brom M, Woliner-van der Weg W, Joosten L, Frielink C, Bouckenooghe T, Rijken P, et al. Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin. Diabetologia. 2014;57(5):950–9.PubMedCrossRef
68.
Reiner T, Kohler RH, Liew CW, Hill JA, Gaglia J, Kulkarni RN, et al. Near-infrared fluorescent probe for imaging of pancreatic β cells. Bioconjugate Chem. 2010;21(7):1362–8.CrossRef
69.
Jodal A, Lankat-Buttgereit B, Brom M, Schibli R, Béhé M. A comparison of three 67/68Ga-labelled exendin-4 derivatives for β-cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelator. EJNMMI Res. 2014;4:31.PubMedPubMedCentralCrossRef
70.
Reiner T, Thurber G, Gaglia J, Vinegoni C, Liew CW, Upadhyay R, et al. Accurate measurement of pancreatic islet β-cell mass using a second-generation fluorescent exendin-4 analog. Proc Natl Acad Sci U S A. 2011;108(31):12815–20.PubMedPubMedCentralCrossRef
71.
Jodal A, Pape F, Becker-Pauly C, Maas O, Schibli R, Béhé M. Evaluation of 111In-labelled exendin-4 derivatives containing different Meprin β-specific cleavable linkers. Cebecauer M, editor. PLoS ONE. 2015;10(4):e0123443.
72.
Vinet L, Lamprianou S, Babič A, Lange N, Thorel F, Herrera PL, et al. Targeting GLP-1 receptors for repeated magnetic resonance imaging differentiates graded losses of pancreatic beta cells in mice. Diabetologia. 2015;58(2):304–12.PubMedCrossRef
73.
Brand C, Abdel-Atti D, Zhang Y, Carlin S, Clardy SM, Keliher EJ, et al. In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent. Bioconjugate Chem. 2014;25(7):1323–30.CrossRef
74.
75.
Massoud TF. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17(5):545–80.PubMedCrossRef
76.
Culver J, Akers W, Achilefu S. Multimodality molecular imaging with combined optical and SPECT/PET modalities. J Nucl Med. 2008;49(2):169–72.PubMedCrossRef
77.
Shokrollahi H. Contrast agents for MRI. Mater Sci Eng C Mater Biol Appl. Elsevier B.V; 2013;33(8):4485–97.
78.
Bruyant PP. Analytic and iterative reconstruction algorithms in SPECT. J Nucl Med. 2002;43(10):1343–58.PubMed
79.
Mariani G, Bruselli L, Kuwert T, Kim EE, Flotats A, Israel O, et al. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging. 2010;37(10):1959–85.PubMedCrossRef
80.
Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani NA. A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology. 1975;114(1):89–98.PubMedCrossRef
81.
82.
83.
Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 2006;101(2):175–83.PubMedCrossRef
84.
Razansky D, Deliolanis NC, Vinegoni C, Ntziachristos V. Deep tissue optical and optoacoustic molecular imaging technologies for pre-clinical research and drug discovery. Curr Pharm Biotechnol. 2012;13(4):504–22.PubMedCrossRef
85.
Sekiguchi Y, Owada J, Oishi H, Katsumata T, Ikeda K, Kudo T, et al. Noninvasive monitoring of β-cell mass and fetal β-cell genesis in mice using bioluminescence imaging. Exp Anim. 2012;61(4):445–51.PubMedCrossRef
86.
Choy G, Choyke P, Libutti SK. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging. 2003;2(4):303–12.PubMedCrossRef
87.
Arifin DR, Bulte JWM. Imaging of pancreatic islet cells. Park Y, Kim K, Pozzilli P, editors. Diabetes Metab Res Rev. 2011;27(8):761–6.
88.
Liu Z, Miller SJ, Joshi BP, Wang TD. In vivo targeting of colonic dysplasia on fluorescence endoscopy with near-infrared octapeptide. Gut. 2013;62(3):395–403.PubMedCrossRef
89.
Saisho Y, Harris PE, Butler AE, Galasso R, Gurlo T, Rizza RA, et al. Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol. 2008;39(5):543–51.PubMedPubMedCentralCrossRef
90.
Watanabe M, Takemura H, Mizoguchi H, Hyodo H, Soga K, Zako T, et al. Development of novel endoscope with NIR camera using real-time video composite method. IFMBE proceedings. Cham: Springer International Publishing; 2014. p. 128–31.
91.
Anlauf M, Eissele R, Schäfer MKH, Eiden LE, Arnold R, Pauser U, et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem. 2003;51(8):1027–40.PubMedCrossRef
92.
Eiden LE, Schäfer MK-H, Weihe E, Schütz B. The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch. 2004;447(5):636–40.PubMedCrossRef
93.
Kung MP, Hou C, Lieberman BP, Oya S, Ponde DE, Blankemeyer E, et al. In vivo imaging of β-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med. 2008;49(7):1171–6.PubMedCrossRef
94.
Singhal T, Ding Y-S, Weinzimmer D, Normandin MD, Labaree D, Ropchan J, et al. Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes. Mol Imaging Biol. 2010;13(5):973–84.PubMedPubMedCentralCrossRef
95.
Schäfer MKH, Hartwig NR, Kalmbach N, Klietz M, Anlauf M, Eiden LE, et al. Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models. Diabetologia. 2013;56(5):1047–56.PubMedPubMedCentralCrossRef
96.
Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51 Suppl 3:S368–76.PubMedCrossRef
97.
Moore A, Bonner-Weir S, Weissleder R. Noninvasive in vivo measurement of beta-cell mass in mouse model of diabetes. Diabetes. 2001;50(10):2231–6.PubMedCrossRef
98.
Tessonnier L, Sebag F, Ghander C, De Micco C, Reynaud R, Palazzo FF, et al. Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab. 2010;95(1):303–7.PubMedCrossRef
99.
Akizawa H, Arano Y, Mifune M, Iwado A, Saito Y, Mukai T, et al. Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides. Nucl Med Biol. 2001;28(7):761–8.PubMedCrossRef
100.
Bird JL, Wright EE, Feldman JM. Pancreatic islets: a tissue rich in serotonin. Diabetes. 1980;29(4):304–8.PubMedCrossRef
101.
Ohta Y, Kosaka Y, Kishimoto N, Wang J, Smith SB, Honig G, et al. Convergence of the insulin and serotonin programs in the pancreatic β-cell. Diabetes. 2011;60(12):3208–16.PubMedPubMedCentralCrossRef
102.
Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem. 2008;56(9):841–51.PubMedPubMedCentralCrossRef
103.
Kolligs F, Fehmann HC, Göke R, Göke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9–39) amide. Diabetes. 1995;44(1):16–9.PubMedCrossRef
104.
Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest. 1995;95(1):417–21.PubMedPubMedCentralCrossRef
105.
Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology. 1992;130(1):159–66.PubMed
106.
Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000;49(5):741–8.PubMedCrossRef
107.
Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270–6.PubMedCrossRef
108.
Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metabol. 1995;80(3):952–7.
109.
Wang Y, Lim K, Normandin M, Zhao X, Cline GW, Ding Y-S. Synthesis and evaluation of [18F]exendin (9–39) as a potential biomarker to measure pancreatic β-cell mass. Nucl Med Biol. Elsevier Inc. 2011; 1–10.
110.
Velikyan I, Bulenga TN, Selvaraju R, Lubberink M, Espes D, Rosenstrom U, et al. Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-exendin-4—impact on the feasibility of insulinoma internal radiotherapy. Am J Nucl Med Mol Imaging. 2015;5(2):109–26.PubMedPubMedCentral
111.
Gotthardt M, van Eerd-Vismale J, Oyen WJG, De Jong M, Zhang H, Rolleman E, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med. 2007;48(4):596–601.PubMedCrossRef
112.
Fujioka Y, Arano Y, Ono M, Uehara T, Ogawa K, Namba S, et al. Renal metabolism of 3′-iodohippuryl Nε-maleoyl-l-lysine (HML)-conjugated fab fragments. Bioconjugate Chem. 2001;12(2):178–85.CrossRef
113.
Zhang B, Jiang B, Chen Y, Huang H, Xie Q, Kang M, et al. Detection of viability of transplanted beta cells labeled with a novel contrast agent - polyvinylpyrrolidone-coated superparamagnetic iron oxide nanoparticles by magnetic resonance imaging. Contrast Media Mol Imaging. 2012;7(1):35–44.PubMedCrossRef
114.
Oishi K, Miyamoto Y, Saito H, Murase K, Ono K, Sawada M, et al. In vivo imaging of transplanted islets labeled with a novel cationic nanoparticle. Rozhkova EA, editor. PLoS ONE. 2013;8(2):e57046.
115.
Lee N, Kim H, Choi SH, Park M, Kim D, Kim HC, et al. Magnetosome-like ferrimagnetic iron oxide nanocubes for highly sensitive MRI of single cells and transplanted pancreatic islets. Proc Natl Acad Sci U S A. 2011;108(7):2662–7.PubMedPubMedCentralCrossRef
116.
Zacharovová K, Berková Z, Jirák D, Herynek V, Vancová M, Dovolilová E, et al. Processing of superparamagnetic iron contrast agent ferucarbotran in transplanted pancreatic islets. Contrast Media Mol Imaging. 2012;7(6):485–93.PubMedCrossRef
117.
Wang P, Yoo B, Yang J, Zhang X, Ross A, Pantazopoulos P, et al. GLP-1R-targeting magnetic nanoparticles for pancreatic islet imaging. Diabetes. 2014;63(5):1465–74.PubMedPubMedCentralCrossRef
118.
Leoni L, Dhyani A, La Riviere P, Vogt S, Lai B, Roman BB. β-Cell subcellular localization of glucose-stimulated Mn uptake by X-ray fluorescence microscopy: implications for pancreatic MRI. Contrast Media Mol Imaging. 2011;6(6):474–81.PubMedPubMedCentralCrossRef
119.
In’t Veld P, Marichal M. Microscopic anatomy of the human islet of Langerhans. Adv Exp Med Biol. 2010;654:1–19.PubMedCrossRef
120.
Clardy SM, Keliher EJ, Mohan JF, Sebas M, Benoist C, Mathis D, et al. Fluorescent exendin-4 derivatives for pancreatic β-cell analysis. Bioconjugate Chem. 2014;25(1):171–7.CrossRef
Metadata
Title
Targets and probes for non-invasive imaging of β-cells
Authors
Andreas Jodal
Roger Schibli
Martin Béhé
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3592-1

Other articles of this Issue 4/2017

European Journal of Nuclear Medicine and Molecular Imaging 4/2017 Go to the issue

Original Article

68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients

Original Article

Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging

Editorial Commentary

Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium

Image of the Month

Diffuse 18F-FDG accumulation in the subarachnoid space detected by PET/CT in a patient with subarachnoid hemorrhage and hyperglycemia

Book Review

THIEME Atlas of Anatomy – Internal Organs , 2nd Edition. Michael Schuenke, Erik Schulte, Udo Schumacher (Editors), Wayne A. Cass (Consulting Editor), Markus Voll, Karl Wesker (Illustrations)

Original Article

Assessment of muscle function using hybrid PET/MRI: comparison of 18F-FDG PET and T2-weighted MRI for quantifying muscle activation in human subjects